Nephros/$NEPH
1D1W1MYTD1Y5YMAX
About Nephros
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
- Ticker
- $NEPH
- Sector
- Industrials
- Primary listing
- NASDAQ
- Employees
- 36
- Headquarters
- South Orange, United States
- Website
- www.nephros.com
Nephros Metrics
BasicAdvanced
$49M
28.43
$0.16
1.53
-
Price and volume
Market cap
$49M
Beta
1.53
52-week high
$6.42
52-week low
$2.66
Average daily volume
27K
Financial strength
Current ratio
4.066
Quick ratio
2.629
Long term debt to equity
3.827
Total debt to equity
7.286
Interest coverage (TTM)
1,642.00%
Profitability
EBITDA (TTM)
1.763
Gross margin (TTM)
61.26%
Net profit margin (TTM)
8.38%
Operating margin (TTM)
7.92%
Effective tax rate (TTM)
0.91%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
7.33%
Return on equity (TTM)
16.10%
Valuation
Price to earnings (TTM)
28.432
Price to revenue (TTM)
2.347
Price to book
4.13
Price to tangible book (TTM)
4.59
Price to free cash flow (TTM)
-73.581
Free cash flow yield (TTM)
-1.36%
Free cash flow per share (TTM)
-0.062
Growth
Revenue change (TTM)
24.20%
Earnings per share change (TTM)
34.27%
3-year revenue growth (CAGR)
19.29%
10-year revenue growth (CAGR)
26.78%
3-year earnings per share growth (CAGR)
-31.00%
10-year earnings per share growth (CAGR)
-13.86%
Nephros News
AllArticlesVideos
Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026
MCAP MediaWire3 weeks ago
Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET
MCAP MediaWire1 month ago
�Nephros Announces Inclusion in the Russell Microcap® Index
MCAP MediaWire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.